Rule 406 under the Securities Act of 1933

This is what our April Q may look like

    Upon sub-license by BioSante of any Product covered in this Agreement or Amendments Nos. 1, 2, or 3 (other than XXXXX), BioSante will pay to Antares the proportion of such upfront payments defined in C below or Milestone Payments defined in paragraph 3.3 actually received, as follows: a) where the payments received by BioSante are XXXXXXXXXXXX from BioSante to Antares then XXXXXXXXXX will be due to Antares, b) where the payments to BioSante arc XXXXXXXXXXXXXXX above the commitment to Antares, the additional amount payable to Antares will be XXX of this excess, and c) where payments received by BioSante are XXXXXXXXXXX the amounts due to Antares, then BioSante will pay Antares XXX of this excess. (For example, if a Milestone Payment of XXXXXX is due from BioSante to Antares, and a sub-licensee pays BioSante a Milestone Payment upon the same milestone of XXXXXX, BioSante will pay Antares XXX of the amount from XXXXXX to XXXXXX (that is, XXXXXX) and BioSante will pay Antares XXX of the XXXXXX excess over XXXXXXXXXXX the XXXXXX Milestone Payment, or XXXXXX) for a total of XXXXXX; [A portion of this section has been omitted pursuant to a request for confidential treatment under, Rule 406 under the Securities Act of 1933 as amended. A copy of this section with the portion intact has been filed separately with the Securities

This is from Biosante Pharmaceuticals Inc